Global Point-of-Care Diagnostics Market Driven by Innovation: Projected Surge with 9-11% Growth by 2028
Growing rates of
infectious illnesses, rising need for quick diagnostic kits, continuous
technical development, and favorable government backing for point-of-care
diagnostics equipment in important countries are the main factors driving the Point-of-Care
Diagnostics market.
Point-of-care diagnostics, or POC
diagnostics, are diagnostic tests performed on patients outside of conventional
laboratories, usually at the patient's place of treatment. These tests are
designed to give quick and easy findings so that medical practitioners may
decide on treatment right away. Fast data delivery, adaptability to different
healthcare environments, simple processes needing little training, and the
capacity to trigger fast clinical actions are some of the key aspects. POC
diagnostics are useful in the diagnosis, monitoring, and treatment of a wide
range of medical disorders. Examples of these applications include diabetes
monitoring, cardiovascular indicators, infectious infections, and pregnancy.
The decentralized structure of POC diagnostics improves access to testing
services, and portable equipment enable testing in many places, especially in
areas with low resources. Pregnancy testing, fast strep tests, and blood
glucose monitoring are a few examples. As technology evolves, new POC
diagnostic tools emerge, fostering efficient and patient-centered healthcare
practices to improve testing speed and accessibility for enhanced patient care
and outcomes.
To know more about the research report, fill
out a quick inquiry for a sample report: https://meditechinsights.com/point-of-care-diagnostics-market/request-sample/
Beyond the Lab: Using Point-of-Care Testing
to Speed Up Diagnosis for Contagious and Chronic Illnesses
The need for sophisticated point-of-care testing is rising as a result of the increasing requirement for prompt and precise identification of infectious and chronic illnesses. The rising incidence of infectious diseases is expected to fuel a particularly strong demand for these cutting-edge diagnostic instruments. Globally, diseases including HIV, hepatitis, influenza, and TB have emerged as serious public health issues. The importance of point-of-care testing in healthcare settings is highlighted by the pressing need to detect these disorders and start the right therapies as soon as possible. In addition to improving illness detection speed and efficiency, these new diagnostics also provide a substantial contribution to the management and control of infectious diseases as a whole. This trend reflects a broader paradigm shift towards proactive and targeted healthcare solutions, where timely diagnosis becomes a key factor in preventing the spread of diseases and improving patient outcomes. For instance,
Next-Generation
Diagnostics: Improving Point-of-Care Testing with Technological Breakthroughs
Recent advances in point-of-care testing (POCT) have been considerably influenced by technological innovations, such as the introduction of multiplexing capabilities into diagnostic methods. This breakthrough enables the simultaneous detection and analysis of many biomarkers or parameters at the patient's bedside, significantly improving diagnostic efficiency. Furthermore, innovations in cellphone-based technologies, such as the use of smartphones, have played a critical role in driving cost-effective mobile healthcare and personalized medicine, providing users with convenient and accessible solutions, and facilitating the integration of diagnostic capabilities into everyday devices. These combined developments help to shape the growth of next-generation diagnostics, improving accessibility and efficiency in healthcare procedures. For instance,
- In November 2022, LumiraDx Limited announced the commercial expansion of its HbA1c test for professional use in various care settings. The test works alongside the LumiraDx Platform to monitor HbA1c levels in known diabetic patients and identify those at risk of developing diabetes.
Furthermore,
the introduction of paper-based assays (PBAs) and lab-on-a-chip (LOC) platforms
has ushered in a new age of reliable, automated, and simple point-of-care
testing. PBAs, noted for their cost-effectiveness, and LOC platforms, built for
miniaturized and integrated diagnostics, help to improve diagnostic process
efficiency and accessibility. Novel assay formats improve the versatility of
point-of-care testing, addressing a wide range of diagnostic demands. The
stability of reagent storage is a significant factor that has been addressed as
these technologies have advanced. Strategies have been developed to allow for
long-term storage of reagents at ambient temperatures, assuring the feasibility
and use of point-of-care testing equipment in a variety of contexts. The
ongoing refining of these technologies has the potential to change diagnostic
capabilities by delivering more accessible and efficient healthcare solutions
globally.
Regional Dynamics of the Point-of-Care
Diagnostics Market
North America has emerged as the
primary focus of the POC diagnostics market, owing to favorable government
regulations, broad knowledge of self-testing, and a high prevalence of
lifestyle illnesses. However, the Asia Pacific region is expected to have the
most rapid expansion in the point-of-care industry. This spike is being driven
by a growing population, an increase in labs and diagnostic facilities, rising
healthcare costs, and the growing influence of local makers of diagnostic kits
and reagents.
Competitive Landscape Analysis
Some of the key players operating in the
market include Abbott Laboratories, Siemens
Healthcare, F. Hoffman-La Roche Ltd, BD (Becton, Dickinson and Company), Trinity Biotech, Sysmex Corporation, Nova Biomedical,
Quidel Corporation
and Danaher Corporation,
among others.
Organic and Inorganic Growth Strategies
Adopted by Players to Establish Their Foothold in the Market
Players operating in this market are adopting both organic and inorganic growth strategies such as collaborations, and acquisitions to garner market share. For instance,
- In January 2023, Trinity Biotech revealed a strategic 5-year partnership with imaware, designating Trinity Biotech as the lab testing partner for imaware™ and aiming to process over 650,000 test kits annually at its advanced New York-based reference lab facility by the third year, with a focus on delivering integrated diagnostic testing solutions and seamless follow-up confirmatory testing for imaware users
The point-of-care diagnostics market is
expected to gain further momentum in the coming years due to the rising need for quick and reliable diagnostic results, growing awareness
of self-testing, increasing prevalence
of lifestyle diseases and aggressive organic and inorganic growth strategies
followed by the players.
Get Personalized Research
Report on Point-of-care Diagnostics Market @ https://meditechinsights.com/point-of-care-diagnostics-market/
Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have successfully completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
Comments
Post a Comment